We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Urine Test Assesses Risk of Kidney Cancer Recurrence at Early Stage

By LabMedica International staff writers
Posted on 05 Sep 2025

Kidney cancer affects about 400,000 people globally each year, with clear cell renal cell carcinoma being the most common form. More...

Around 20% of patients who undergo curative surgery relapse within five years, requiring frequent CT scans to check for recurrence. These scans expose patients to radiation, cause anxiety, and add costs. Now, a new international study has shown that a simple urine test can reduce the need for half of these scans while still detecting recurrence early.

The study, led by Lund University (Lund, Sweden) and conducted in collaboration with 23 hospitals across ten countries, investigated a diagnostic test based on glycosaminoglycans, or sugar molecules, found in urine. This biomarker panel, called the GAGome test, evaluates the molecular composition of urine to assess cancer recurrence risk. Unlike relying on a single molecule, the test uses a set of biomarkers to provide a stronger diagnostic foundation.

The study followed 134 patients who had undergone curative surgery for kidney cancer, combining regular scans with urine testing. Results showed that the GAGome test detected recurrence in 90% of relapsed patients and correctly identified 97% of those without relapse when results were negative. The findings, published in European Urology Oncology, demonstrated the test’s high sensitivity and reliability in clinical monitoring.

The urine test offers significant advantages over scans alone, which can capture small, uncertain changes that lead to repeated imaging. By incorporating urine tests, clinicians can reduce unnecessary scans, ease patient anxiety, and identify recurrence earlier. The approach could lower healthcare costs while providing safer, more effective follow-up care. Researchers are continuing the study with additional participants to confirm the results by the end of 2025.

“A scan often captures small changes that are not large enough for taking a tissue sample, and therefore, we don’t know if they are signs that the cancer has returned. Our only option is then to carry out more frequent scans, which cause anxiety for the patients and often have little benefit. Using urine tests enables us to better assess the risk, offer more effective checks and potentially halve the number of scans,” said Saeed Dabestani, Associate Professor at Lund University and senior urology consultant at Kristianstad Central Hospital.

“The GAGome test is based on a set of biomarkers, rather than just one molecule, which provides a more robust foundation for making decisions about treatment,” said Saeed Dabestani, associate professor at Lund University who led the study. “If the test comes back negative, we are more or less certain that there is no recurrence, but if the test is positive, we must continue to investigate.”


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
ESR Analyzer
TEST1 2.0
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more

Industry

view channel
Image: Lunit and Agilent Technologies are collaborating to develop AI-powered companion diagnostics. (Photo courtesy of Lunit)

Lunit and Agilent Partner to Develop AI-Powered Cancer Diagnostics

Biomarker testing plays a critical role in precision oncology, guiding tailored therapies for patients. However, current methods often rely heavily on manual interpretation, which can introduce variability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.